Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
$0.00
+50.0%
$0.19
$0.00
$3.40
$31K-17.745,371 shs330 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$2.00
-3.8%
$1.92
$1.42
$12.33
$73.35M1.34623,981 shs615,670 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$4.81
-3.2%
$4.66
$4.01
$9.33
$79.10M1.32195,385 shs46,468 shs
TELA Bio, Inc. stock logo
TELA
TELA Bio
$1.70
-8.1%
$1.22
$0.86
$5.59
$73.18M0.78231,084 shs166,026 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
+50.00%-99.85%-99.85%-99.77%-99.85%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-3.85%-11.89%+6.38%-1.48%-78.90%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
-3.22%-2.24%-0.21%+3.44%-11.74%
TELA Bio, Inc. stock logo
TELA
TELA Bio
-8.11%-10.05%+71.72%-27.66%-69.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
N/AN/AN/AN/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
4.0858 of 5 stars
3.32.00.04.33.70.01.3
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
2.5243 of 5 stars
3.62.00.00.02.90.01.3
TELA Bio, Inc. stock logo
TELA
TELA Bio
2.4843 of 5 stars
3.43.00.00.02.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
0.00
N/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$9.75387.50% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.25
Buy$11.67142.55% Upside
TELA Bio, Inc. stock logo
TELA
TELA Bio
2.75
Moderate Buy$7.25326.47% Upside

Current Analyst Ratings Breakdown

Latest HYBT, SRTS, INO, and TELA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $13.00
4/4/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/21/2025
TELA Bio, Inc. stock logo
TELA
TELA Bio
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $7.00
3/21/2025
TELA Bio, Inc. stock logo
TELA
TELA Bio
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$5.00 ➝ $2.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$6.00 ➝ $5.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
$80K0.39N/AN/A$0.38 per share0.00
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$283.10K259.09N/AN/A$5.16 per share0.39
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$39.49M2.00$0.05 per share96.29$2.98 per share1.61
TELA Bio, Inc. stock logo
TELA
TELA Bio
$71.22M0.94N/AN/A$0.77 per share2.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
-$270KN/A0.00N/A-453.55%-6.43%-4.43%N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$3.19N/AN/AN/AN/A-118.17%-83.47%8/6/2025 (Estimated)
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M$0.1012.0320.91N/A15.90%12.60%11.38%8/6/2025 (Estimated)
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$46.66M-$1.41N/AN/AN/A-60.49%-556.18%-63.13%8/11/2025 (Estimated)

Latest HYBT, SRTS, INO, and TELA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.04-$0.16-$0.20-$0.16$7.23 million$8.34 million
5/13/2025Q1 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million
5/8/2025Q1 2025
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$0.21-$0.25-$0.04-$0.25$17.35 million$18.52 million
3/20/2025Q4 2024
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$0.24-$0.23+$0.01-$0.23$23.17 million$17.65 million
3/18/2025Q4 2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.87-$0.69+$0.18-$0.60$0.03 million$0.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
N/A
0.35
0.34
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.88
3.88
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
10.52
7.89
TELA Bio, Inc. stock logo
TELA
TELA Bio
14.22
2.62
1.81

Institutional Ownership

CompanyInstitutional Ownership
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%
TELA Bio, Inc. stock logo
TELA
TELA Bio
94.35%

Insider Ownership

CompanyInsider Ownership
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
89.24%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
8.90%
TELA Bio, Inc. stock logo
TELA
TELA Bio
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
6103.25 million11.11 millionNot Optionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million25.45 millionOptionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.45 million14.85 millionOptionable
TELA Bio, Inc. stock logo
TELA
TELA Bio
12039.56 million37.03 millionOptionable

Recent News About These Companies

TELA Bio (NASDAQ:TELA) Cut to Sell at Wall Street Zen
TELA Bio (NASDAQ:TELA) Upgraded at Wall Street Zen
TELA Bio Appoints Jeffrey Blizard as President

New MarketBeat Followers Over Time

Media Sentiment Over Time

Heyu Biological Technology stock logo

Heyu Biological Technology OTCMKTS:HYBT

$0.0003 +0.00 (+50.00%)
As of 06/12/2025

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$2.00 -0.08 (-3.85%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$2.04 +0.04 (+2.25%)
As of 06/13/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$4.81 -0.16 (-3.22%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$4.80 0.00 (-0.10%)
As of 06/13/2025 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

TELA Bio stock logo

TELA Bio NASDAQ:TELA

$1.70 -0.15 (-8.11%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.70 +0.01 (+0.29%)
As of 06/13/2025 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.